Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients.
Alicja PuszkielGuillaume BianconiBlaise PasquiersDavid BalakirouchenaneJennifer ArrondeauPascaline Boudou-RouquetteMarie-Claire BretagneJoe-Elie SalemXavier DeclèvesMichel VidalNora KramkimelSarah GueganSelim AractingiOlivier HuillardJérôme AlexandreMarie WislezFrançois GoldwasserBenoit BlanchetPublished in: British journal of cancer (2024)
Clinical trials are warranted to confirm the non-inferiority of extended-interval compared to standard regimen.